Hang Lu, Wang Enkang, Feng Ya, Zhou Yan, Meng Yangyang, Jiang Fengru, Yuan Jianye
Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Front Microbiol. 2022 Nov 21;13:1024822. doi: 10.3389/fmicb.2022.1024822. eCollection 2022.
The effect of Shugan Decoction (SGD) on intestinal motility and visceral hypersensitivity in Water avoid stress (WAS)-induced diarrhea predominant irritable bowel syndrome (IBS-D) model rats has been confirmed. However, the mechanisms of its action involved in the treatment of IBS-D need to be further studied. Intestinal microbiota plays an important role in maintaining intestinal homeostasis and normal physiological function. Changes in the intestinal microbiota and its metabolites are thought to participate in the pathophysiological process of IBS.
This study aimed to analyze the influence of SGD on intestinal microbiota and fecal metabolites in IBS-D rats by multiple omics techniques, including metagenomic sequencing and metabolomics.
We measured the intestinal motility and visceral sensitivity of three groups of rats by fecal pellets output and colorectal distension (CRD) experiment. In addition, metagenome sequencing analysis was performed to explore the changes in the number and types of intestinal microbiota in IBS-D model rats after SGD treatment. Finally, we also used untargeted metabolomic sequencing to screen the metabolites and metabolic pathways closely related to the therapeutic effect of SGD.
We found that compared with the rats in the control group, the fecal pellets output of the rats in the WAS group increased and the visceral sensitivity threshold was decreased ( < 0.05). Compared with the rats in the WAS group, the fecal pellets output of the SGD group was significantly decreased, and the visceral sensitivity threshold increased ( < 0.05). Besides, compared with the rats in the WAS group, the relative abundance of increased in SGD group, while that of decreased at the phylum level, and at the species level, the relative abundance of , and in SGD group increased, but that of decreased. In addition, compared with the WAS group, several metabolic pathways were significantly changed in SGD group, including Taurine and hypotaurine metabolism, Purine metabolism, Sulfur metabolism, ABC transporters, Arginine and proline metabolism and Bile secretion.
SGD can regulate specific intestinal microbiota and some metabolic pathways, which may explain its effect of alleviating visceral hypersensitivity and abnormal intestinal motility in WAS-induced IBS-D rats.
疏肝汤(SGD)对水浸束缚应激(WAS)诱导的腹泻型肠易激综合征(IBS-D)模型大鼠肠道动力和内脏高敏感性的影响已得到证实。然而,其治疗IBS-D的作用机制仍需进一步研究。肠道微生物群在维持肠道稳态和正常生理功能中起重要作用。肠道微生物群及其代谢产物的变化被认为参与了IBS的病理生理过程。
本研究旨在通过宏基因组测序和代谢组学等多种组学技术,分析SGD对IBS-D大鼠肠道微生物群和粪便代谢产物的影响。
通过粪便颗粒排出量和结直肠扩张(CRD)实验测定三组大鼠的肠道动力和内脏敏感性。此外,进行宏基因组测序分析,以探讨SGD治疗后IBS-D模型大鼠肠道微生物群数量和种类的变化。最后,我们还使用非靶向代谢组学测序筛选与SGD治疗效果密切相关的代谢产物和代谢途径。
我们发现,与对照组大鼠相比,WAS组大鼠的粪便颗粒排出量增加,内脏敏感性阈值降低(<0.05)。与WAS组大鼠相比,SGD组大鼠的粪便颗粒排出量显著减少,内脏敏感性阈值升高(<0.05)。此外,与WAS组大鼠相比,SGD组门水平上的相对丰度增加,而的相对丰度降低,在种水平上,SGD组的、和的相对丰度增加,但的相对丰度降低。此外,与WAS组相比,SGD组有几个代谢途径发生了显著变化,包括牛磺酸和低牛磺酸代谢、嘌呤代谢、硫代谢、ABC转运蛋白、精氨酸和脯氨酸代谢以及胆汁分泌。
SGD可以调节特定的肠道微生物群和一些代谢途径,这可能解释了其缓解WAS诱导的IBS-D大鼠内脏高敏感性和肠道动力异常的作用。